Pre-Market Review: MannKind, Ariad Pharma, Galena Biopharma, and Novavax Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, June 28, 2013 LONDON, June 28, 2013 /PRNewswire/ -- On Thursday, June 27, 2013, shares in biotechnology companies ended mostly higher, tracking gains in the broader market which rose for a third successive trading session. The major movers in the sector included MannKind Corporation (NASDAQ: MNKD), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), and Novavax Inc. (NASDAQ: NVAX). AAAResearchReports.com initiated preliminary technical research on MNKD, ARIA, GALE, and NVAX. These free reports are accessible by signing today at: http://www.aaaresearchreports.com/register/ Shares in MannKind Corporation rallied on Thursday, tracking gains in the broader market. The company's shares ended the day 3.11% higher at $6.64 after oscillating between $6.51 and $6.68. A total of 6.27 million shares were traded which is below the daily average volume of 9.03 million. MannKind's shares have gained 97.03% in the last three months, thus outperforming the S&P 500. Furthermore, the stock has a 52-week high of $8.06. The free technical analysis on MNKD is available by signing up at: http://www.AAAResearchReports.com/MNKD062813.pdf Ariad Pharmaceuticals Inc.'s stock closed slightly lower on Thursday even as the broader market posted gains. The company's shares fluctuated between $17.19 and $18.05 before finishing the day 0.68% lower at $17.55. A total of 1.70 million shares were traded which is below the daily average volume of 2.87 million. Despite Thursday's pullback, the company's shares have gained 7.14% in the last three trading sessions. Register now to download free research on ARIA at: http://www.AAAResearchReports.com/ARIA062813.pdf Shares in Galena Biopharma Inc. rallied on Thursday, extending their gains from previous trading session. The company's shares closed 5.06% higher at $2.18. A total of 1.51 million shares were traded which is below the daily average volume of 1.93 million. The stock has gained 8.73% in the last two trading sessions. The gains have pushed the stock above its 200-day moving average. Nonetheless, the stock is still trading below its 50-day moving average. A free report on GALE can be accessed by registering at: http://www.AAAResearchReports.com/GALE062813.pdf Novavax Inc.'s stock moved higher on Thursday, reversing some of its recent losses. The company's shares oscillated between $1.93 and $1.99 before closing the day at $1.98, up 1.54%. A total of 590,817 shares were traded which is below the daily average volume of 1.42 million. The company's shares are now down 2.46% in the last three trading sessions. In the last three months, the stock has dropped by 9.17%. Moreover, the stock has a 52-week high of $2.77. Register with AAA Research Reports and download research on NVAX for free at: http://www.AAAResearchReports.com/NVAX062813.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE AAA Research Reports Contact: AAAresearchreports.com Phone #: + 1 (646) 396-9126
Pre-Market Review: MannKind, Ariad Pharma, Galena Biopharma, and Novavax
Press spacebar to pause and continue. Press esc to stop.